Your browser doesn't support javascript.
loading
Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice / 임상당뇨병
Journal of Korean Diabetes ; : 135-140, 2017.
Article Dans Coréen | WPRIM | ID: wpr-727037
ABSTRACT
Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are newer classes of glucose-lowering agents that are currently widely used in clinical practice. Their glycemic efficacy and cardiovascular safety have been well proven, and recent large clinical trials even have shown cardiovascular benefits of SGLT2 inhibitors. However, data regarding drug-related long-term safety remain inconclusive. Recently, several safety issues related to DPP-4 inhibitors and SGLT2 inhibitors have been raised by cardiovascular outcome trials or post-marketing pharmacoepidemiological studies. In this review, we summarize emerging safety issues regarding the use of DPP-4 inhibitors and SGLT2 inhibitors in type 2 diabetes and suggest how to interpret and apply these results to clinical practice.
Sujets)

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Sodium / Diabète / Inhibiteurs de la dipeptidyl-peptidase IV / Glucose langue: Coréen Texte intégral: Journal of Korean Diabetes Année: 2017 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Sodium / Diabète / Inhibiteurs de la dipeptidyl-peptidase IV / Glucose langue: Coréen Texte intégral: Journal of Korean Diabetes Année: 2017 Type: Article